P. Boers

发表

Impact of antigen expression kinetics on the effectiveness of HIV‐specific cytotoxic T lymphocytes

M. Baalen, A. Osterhaus, C. Baalen, 2002, European journal of immunology.

CCR5, GPR15, and CXCR6 Are Major Coreceptors of Human Immunodeficiency Virus Type 2 Variants Isolated from Individuals with and without Plasma Viremia

H. Schuitemaker, A. Osterhaus, P. Boers, 2005, Journal of Virology.

Decline of simian immunodeficiency virus (SIV)-specific cytotoxic T lymphocytes in the peripheral blood of long-term nonprogressing macaques infected with SIVmac32H-J5.

A. Osterhaus, G. van Amerongen, S. Norley, 1999, The Journal of infectious diseases.

iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy

À. Olvera, J. Martinez-Picado, C. Brander, 2019, Trials.

CCR5-restricted HIV type 2 variants from long-term aviremic individuals are less sensitive to inhibition by beta-chemokines than low pathogenic HIV type 1 variants.

H. Schuitemaker, A. Osterhaus, P. Boers, 2008, AIDS research and human retroviruses.

Coreceptor Usage of Human Immunodeficiency Virus Type 2 Primary Isolates and Biological Clones Is Broad and Does Not Correlate with Their Syncytium-Inducing Capacities

A. Osterhaus, M. Schutten, C. Guillon, 1998, Journal of Virology.

Antibody-Mediated Enhancement of Human Immunodeficiency Virus Type 1 Infectivity Is Determined by the Structure of gp120 and Depends on Modulation of the gp120-CCR5 Interaction

A. Osterhaus, M. Schutten, C. Guillon, 2002, Journal of Virology.

Characterization of recombinant influenza A virus as a vector for HIV-1 p17Gag.

A. Osterhaus, G. Rimmelzwaan, L. Dekker, 2009, Vaccine.

Kinetics of Antiviral Activity by Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes (CTL) and Rapid Selection of CTL Escape Virus In Vitro

M. Schutten, C. Baalen, P. Boers, 1998, Journal of Virology.

Antiviral Resistance of Biologic HIV‐2 Clones Obtained From Individuals on Nucleoside Reverse Transcriptase Inhibitor Therapy

A. Osterhaus, M. Schutten, C. Guillon, 2000, Journal of acquired immune deficiency syndromes.

Construction and characterisation of infectious recombinant HIV-1 clones containing CTL epitopes from structural proteins in Nef.

A. Osterhaus, C. Guillon, E. Verschuren, 2002, Journal of virological methods.

Reply to Darcis and Berkhout.

C. Boucher, H. Pham, D. A. van de Vijver, 2018, The Journal of infectious diseases.

HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy

C. Boucher, H. Pham, D. A. van de Vijver, 2018, The Journal of infectious diseases.

Chapter 3 HIV-1 resistance dynamics in patients with virological failure to dolutegravir maintenance monotherapy .

C. Boucher, R. Schuurman, T. Mesplède, 2018 .

Macrophage Tropism of Human Immunodeficiency Virus Type 1 Facilitates In Vivo Escape from Cytotoxic T-Lymphocyte Pressure

A. Osterhaus, M. Schutten, C. Guillon, 2001, Journal of Virology.

Antibody response in cats to the envelope proteins of feline immunodeficiency virus: identification of an immunodominant neutralization domain.

Marian C. Horzinek, R. Meloen, L. Keldermans, 1994, Virology.

In vitro replication capacity of HIV-2 variants from long-term aviremic individuals.

Hanneke Schuitemaker, H. Schuitemaker, A. Osterhaus, 2006, Virology.

Broadening of coreceptor usage by human immunodeficiency virus type 2 does not correlate with increased pathogenicity in an in vivo model.

P. Rácz, M. Schutten, C. Guillon, 2000, The Journal of general virology.

Impact of natural sequence variation in the V2 region of the envelope protein of human immunodeficiency virus type 1 on syncytium induction: a mutational analysis.

A. Osterhaus, A. Andeweg, P. Boers, 1995, The Journal of general virology.

Genotypic and Phenotypic Characterization of Replication-Competent HIV-2 Isolated from Controllers and Progressors

P. Boers, R. Gruters, Ronald J. Overmars, 2023, Viruses.